Aarti Pharmalabs (AARTIPHARM) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
20 Oct, 2026Executive summary
Standalone Q1 FY26 revenue fell 4.6% YoY to ₹37,531.06 lakh, while EBITDA rose 13.9% to ₹952mn and net profit rose 8.7% to ₹5,122.08 lakh.
FY26 growth plans center on CDMO expansion, Atali capacity and higher Xanthine output; consolidated comparisons are affected by Ganesh Polychem’s move to JV equity accounting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aarti Pharmalabs
- Xanthine and CDMO growth plans counter Q2 profit pressure and a forex loss.AARTIPHARM
Q2 25/26 - FY24 profit and margins rose as FY25 capacity investment accelerates.AARTIPHARMQ4 23/24
- Revenue and PAT grew YoY as EBITDA margin narrowed 115 bps.AARTIPHARMQ1 24/25
- H1 growth and FY25 guidance face CDMO timing and Chinese price pressures.AARTIPHARMQ2 24/25
- Record Q3 earnings and broad-based growth lift the FY25 outlook.AARTIPHARMQ3 25/26
- Record FY25 earnings underpin FY26 growth plans and major capacity expansion.AARTIPHARMQ4 24/25
- Profits fell YoY as Atali delays and API pressure weighed; CDMO and Xanthine expansion underpin growth.AARTIPHARMQ3 25/26
- Record CDMO sales and expansion plans anchor 15%-18% growth guidance.AARTIPHARMQ4 25/26
- Q1 growth and capacity expansion support a 15%–18% multi-year CAGR target.AARTIPHARMQ1 26/27